What is a key focus of care for a patient who has received fibrinolytic therapy and is in a monitored bed on a stroke unit?

A key focus of care for a patient who has received fibrinolytic therapy, particularly within a monitored bed on a stroke unit, is assessing for signs of intracranial bleeding. Fibrinolytic therapy is used to dissolve blood clots and can significantly improve outcomes in patients suffering from certain types of strokes. However, it also carries a risk of serious side effects, including intracranial hemorrhage.

Monitoring for signs of bleeding is crucial. This includes observing for symptoms such as sudden changes in consciousness, severe headache, or neurological deficits that may suggest bleeding in the brain. Identifying these symptoms early can be critical in managing any complications that arise as a result of the therapy.

While managing blood pressure, ensuring airway, breathing, and circulation, and managing glucose levels are also important components of patient care, the potential for intracranial bleeding is a direct consequence of fibrinolytic therapy that requires immediate attention and specific assessment. Thus, vigilance for intracranial bleeding becomes a focal point of care in these patients.